Human Placenta Extract (HPH) Suppresses Inflammatory Responses in TNF-α/IFN-γ-Stimulated HaCaT Cells and a DNCB Atopic Dermatitis (AD)-Like Mouse Model
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Atopic dermatitis (AD), a chronic inflammatory disease, severely interferes with patient life. Human placenta extract (HPH; also known as human placenta hydrolysate) is a rich source of various bioactive substances and has widely been used to dampen inflammation, improve fatigue, exert anti-aging effects, and promote wound healing. However, information regarding HPH’s incorporation in AD therapies is limited. Therefore, this study aimed to evaluate HPH’s effective potential in treating AD using tumor necrosis factor (TNF)-α/interferon (IFN)-γ-stimulated human keratinocytes (HaCaT), immunized splenocytes, and a 2,4-dinitrochlorobenzene (DNCB)-induced AD mouse model. In TNF-α /IFN-γ-stimulated HaCaT cells, HPH markedly reduced the production of reactive oxygen species (ROS) and restored the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), superoxide dismutase 1(SOD1), catalase, and filaggrin (FLG). HPH reduced interleukin (IL)-6; thymusand activation-regulated chemokine (TARC); thymic stromal lymphopoietin (TSLP); and regulated upon activation, normal T cell expressed and presumably secreted (RANTES) levels and inhibited nuclear factor kappa B phosphorylation. Additionally, HPH suppressed the T helper 2 (Th2) immune response in immunized splenocytes. In the AD-like mouse model, it significantly mitigated the DNCB-induced elevation in infiltrating mast cells and macrophages, epidermal thickness, and AD symptoms. HPH also reduced TSLP levels and prevented FLG downregulation. Furthermore, it decreased the expression levels of IL-4, IL-5, IL-13, TARC, RANTES, and immunoglobulin E (IgE) in serum and AD-like skin lesion. Overall, our findings demonstrate that HPH effectively inhibits AD development and is a potentially useful therapeutic agent for AD-like skin disease.
Abstract
Atopic dermatitis (AD), a chronic inflammatory disease, severely interferes with patient life. Human placenta extract (HPH; also known as human placenta hydrolysate) is a rich source of various bioactive substances and has widely been used to dampen inflammation, improve fatigue, exert anti-aging effects, and promote wound healing. However, information regarding HPH’s incorporation in AD therapies is limited. Therefore, this study aimed to evaluate HPH’s effective potential in treating AD using tumor necrosis factor (TNF)-α/interferon (IFN)-γ-stimulated human keratinocytes (HaCaT), immunized splenocytes, and a 2,4-dinitrochlorobenzene (DNCB)-induced AD mouse model. In TNF-α /IFN-γ-stimulated HaCaT cells, HPH markedly reduced the production of reactive oxygen species (ROS) and restored the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), superoxide dismutase 1(SOD1), catalase, and filaggrin (FLG). HPH reduced interleukin (IL)-6; thymusand activation-regulated chemokine (TARC); thymic stromal lymphopoietin (TSLP); and regulated upon activation, normal T cell expressed and presumably secreted (RANTES) levels and inhibited nuclear factor kappa B phosphorylation. Additionally, HPH suppressed the T helper 2 (Th2) immune response in immunized splenocytes. In the AD-like mouse model, it significantly mitigated the DNCB-induced elevation in infiltrating mast cells and macrophages, epidermal thickness, and AD symptoms. HPH also reduced TSLP levels and prevented FLG downregulation. Furthermore, it decreased the expression levels of IL-4, IL-5, IL-13, TARC, RANTES, and immunoglobulin E (IgE) in serum and AD-like skin lesion. Overall, our findings demonstrate that HPH effectively inhibits AD development and is a potentially useful therapeutic agent for AD-like skin disease.
참고문헌 (47)
- Peng W, "Pathogenesis of atopic dermatitis", Clin. Exp. Allergy, 45, pp.566~574 (2015)
- Thomsen SF, "Atopic dermatitis : natural history, diagnosis, and treatment", ISRN Allergy, 2014, pp.354250~ (2014)
- Otsuka A, "The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis", Immunol. Rev, 278, pp.246~262 (2017)
- Bin L, "Genetic and epigenetic studies of atopic dermatitis", Allergy Asthma Clin. Immunol, 12, pp.52~ (2016)
- Leung DY, "New insights into atopic dermatitis", J. Clin. Invest, 113, pp.651~657 (2004)
- Novak N, "Allergic and nonallergic forms of atopic diseases", J. Allergy Clin. Immunol, 112, pp.252~262 (2003)
- Agrawal R, "Skin barrier defects in atopic dermatitis", Curr. Allergy Asthma Rep, 14, pp.433~ (2014)
- Proksch E, "Role of the epidermal barrier in atopic dermatitis", J. Dtsch Dermatol. Ges, 7, pp.899~910 (2009)
- Nicol NH, "Anatomy and physiology of the skin", Dermatol. Nurs, 17, pp.62~ (2005)
- Mori T, "Comparison of skin barrier function and sensory nerve electric current perception threshold between IgE-high extrinsic and IgE-normal intrinsic types of atopic dermatitis", Br. J. Dermatol, 162, pp.83~90 (2010)
- Mestrallet G, "Skin immunity and tolerance : focus on epidermal keratinocytes expressing HLA-G", Front. Immunol, 12, pp.772516~ (2021)
- Nygaard U, "TSLP, IL-31, IL-33 and sST2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis", J. Eur. Acad. Dermatol. Venereol, 30, pp.1930~1938 (2016)
- Elias PM, "Abnormal skin barrier in the etiopathogenesis of atopic dermatitis", Curr. Allergy Asthma Rep, 9, pp.265~272 (2009)
- Chieosilapatham P, "Keratinocytes : innate immune cells in atopic dermatitis", Clin. Exp. Immunol, 204, pp.296~309 (2021)
- Seegraber M, "Dupilumab for treatment of atopic dermatitis", Expert. Rev. Clin. Pharmacol, 11, pp.467~474 (2018)
- Wollenberg A, "Tralokinumab for moderate-to-severe atopic dermatitis : results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials(ECZTRA 1 and ECZTRA 2)", Br. J. Dermatol, 184, pp.437~449 (2021)
- Bieber T, "Abrocitinib versus placebo or dupilumab for atopic dermatitis", N Engl. J. Med, 384, pp.1101~1112 (2021)
- Queille C, "Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood", Pediatr. Dermatol, 1, pp.246~253 (1984)
- Czarnowicki T, "Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march", J. Allergy Clin. Immunol, 139, pp.1723~1734 (2017)
- Noreen S, "Dexamethasone : therapeutic potential, risks, and future projection during COVID-19pandemic", Eur. J. Pharmacol, 894, pp.173854~ (2021)
- Poggioli R, "Dexamethasone reduces energy expenditure and increases susceptibility to diet-induced obesity in mice", Obesity (Silver Spring), 21, pp.E415~E420 (2013)
- Shen S, "Myricanol rescues dexamethasone-induced muscle dysfunction via a sirtuin 1-dependent mechanism", J. Cachexia Sarcopenia Muscle, 10, pp.429~444 (2019)
- Chang PY, "Human placental extract activates a wide array of gene expressions related to skin functions", Sci. Rep, 12, pp.11031~ (2022)
- Kwon TR, "Human placental extract exerts hair growth-promoting effects through the GSK-3beta signaling pathway in human dermal papilla cells", Int. J. Mol. Med, 36, pp.1088~1096 (2015)
- Lee TH, "Human placenta hydrolysate promotes liver regeneration via activation of the cytokine", growth factor-mediated pathway and anti-oxidative effect, 2019, pp.42, 607~616
- Shin EH, "Effects of human placenta extract(Laennec)on ligament healing in a rodent model", Biol. Pharm. Bull, 42, pp.1988~1995 (2019)
- Bak DH, "Anti-apoptotic effects of human placental hydrolysate against hepatocyte toxicity in vivo and in vitro", Int. J. Mol. Med, 42, pp.2569~2583 (2018)
- Kim EH, "Antiviral effects of human placenta hydrolysate(Laennec((R)))against SARS-CoV-2 in vitro and in the ferret model", J. Microbiol, 59, pp.1056~1062 (2021)
- Lee KH, "Anti-inflammatory and analgesic effects of human placenta extract", Nat. Prod. Res, 25, pp.1090~1100 (2011)
- Lee S-H, "Anti-allergic effect of Lactobacillus rhamnosus IDCC 3201 isolated from breast milk-fed Korean infant", Kor. J. Microbiol, 52, pp.18~24 (2016)
- Lee JW, "Pinus densiflora bark extract ameliorates 2, 4-dinitrochlorobenzene-induced atopic dermatitis in NC", Nga mice by regulating Th1, Phytother. Res, pp.2018, 32[DOI]
- Liu J, "Reactive oxygen species(ROS)scavenging biomaterials for anti-inflammatory diseases : from mechanism to therapy", J. Hematol. Oncol, 16, pp.116~ (2023)
- Rizwan S, "Reactive oxygen species in inflammation and tissue injury", Antioxidants & Redox Signaling (2014)
- Elisyutina O, "The experience of atopic dermatitis treatment Wit «Laennek»(«Japan bioproducts industry Co., LTD», JAPAN) in Russia", Russian J. Allergy, 7, pp.97~104 (2010)
- Bak Dh, "Antioxidant effect of human placenta hydrolysate against oxidative stress on muscle atrophy", J. Cell. Physiol, 234, pp.1643~1658 (2019)
- Kawakami T, "Mast cells in atopic dermatitis", Curr. Opin. Immunol, 21, pp.666~678 (2009)
- Mack MR, "The itch–scratch cycle : a neuroimmune perspective", Trends Immunol, 39, pp.980~991 (2018)
- Esnault S, "Essential mechanisms of differential activation of eosinophils by IL-3 compared to GM-CSF and IL-5", Crit. Rev. Immunol, 36, pp.429~444 (2016)
- Song TW, "Increased serum thymus and activation-regulated chemokine and cutaneous T cell-attracting chemokine levels in children with atopic dermatitis", Clin. Exp. Allergy, 36, pp.346~351 (2006)
- Luster AD, "The role of chemokines in linking innate and adaptive immunity", Curr. Opin. Immunol, 14, pp.129~135 (2002)
- Marques-Mejias A, "Skin as the target for allergy prevention and treatment", Annals of Allergy, Asthma & Immunology (2024)
- Nakatsuji T, "Antimicrobials from human skin commensal bacteria protect against and are deficient in atopic dermatitis", Sci. Transl. Med, 9 (2017)
- Smith AR, "The skin as a route of allergen exposure: part I. immune components and mechanisms", Curr. Allergy Asthm. R, 17 (2017)
- Nicotera P, "Caspase-14 and epidermis maturation", Nat. Cell Biol, 9, pp.621~622 (2007)
- Denecker G, "Caspase-14 protects against epidermal UVB photodamage and water loss", Nat. Cell Biol, 9, pp.666-U101~ (2007)
- Kim BE, "Significance of skin barrier dysfunction in atopic dermatitis", Allergy Asthma Immun, 10, pp.207~215 (2018)
- Cultrone A, "The NF-κB binding site located in the proximal region of the TSLP promoter is critical for TSLP modulation in human intestinal epithelial cells", Eur. J. Immunol, 43, pp.1053~1062 (2013)